Researchers at Boston University School of Medicine (BUSM) in the USA, in collaboration with Johns Hopkins University, have identified a potential new biomarker and therapeutic target for melanoma. The novel cell screening method used in the study also clarifies the process behind tumor metastasis and may allow the identification of biomarkers for other aggressive cancers. The findings now appear online in Cancer Research.
According to the American Cancer Society, melanoma is the most serious type of skin cancer and one in 55 people will be diagnosed with it during their lifetime. Previous research has found that metastasis causes more than 90% of solid tumor deaths throughout the world and is particularly aggressive in melanoma.
Role of Neuropilin-2
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze